Aug 13 (Reuters) - Amgen (AMGN.O) has sued Samsung's biologics unit (207940.KS) in New Jersey federal court over its proposed biosimilar versions of Amgen's blockbuster bone drugs Prolia and Xgeva.
Dec 18 - Amgen's (AMGN.O) leukemia drug Blincyto infringes patents owned by Germany's Lindis Biotech, a Delaware federal jury said in a verdict made public on Wednesday, awarding Lindis $50.3 million
total 1 pages, 2 items